HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
TENX
Tenax Therapeutics, Inc.
There isn't enough reported data to score TENX yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
TENX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Strong |
TENX's balance sheet is currently strong, but its profitability is weak. There isn't enough data to rate its revenue and cash flow.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
TENX PE Valuation
TENX has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
TENX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect TENX's earnings, revenue and profitability to hold roughly steady. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
TENX has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus TENX down 100%.
TENX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2022 | -$3,806.42 | +$1,389.95 |
| Q2 2022 | -$4,150.83 | +$1,093.54 |
| Q1 2022 | -$4,492.43 | +$959.94 |
| Q4 2021 | -$6,943.68 | -$3,507.31 |
| Q3 2021 | -$5,196.37 | -$610.16 |
| Q2 2021 | -$5,244.37 | -$418.16 |
| Q1 2021 | -$5,452.37 | -$546.16 |
| Q4 2020 | -$3,436.37 | +$1,389.84 |
TENX lost $1.15 per share over the past year, a smaller loss than the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
TENX Quarterly Revenue
TENX and HIMS do not have enough comparable growth data to identify a winner.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over TENX on cash generation, producing positive trailing cash flow while its opponent burns cash.
TENX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$12.5M | -$3.3M |
| Q2 2026 | -$14.2M | -$7.9M |
| Q1 2026 | -$9.3M | -$2.3M |
| Q4 2025 | -$13.4M | -$9.9M |
| Q3 2025 | -$9.2M | -$6.1M |
| Q4 2024 | -$3.5M | -$2.4M |
| Q3 2024 | -$3.1M | -$1M |
| Q4 2023 | -$1.2M | +$1.1M |
TENX has burned cash in almost every quarter: −$49M over the past year, against −$26M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over TENX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
TENX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +1043% | +3.1M shares |
| 3 years | +31578% | +3.4M shares |
TENX has 3M diluted shares, up 1043% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
TENX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2024 | -12.7x | Net Cash |
| Q2 2024 | -1.7x | Net Cash |
| Q1 2024 | -4.4x | Net Cash |
| Q4 2023 | -1.1x | Net Cash |
| Q3 2022 | -0.3x | Net Cash |
| Q2 2022 | -0.6x | Net Cash |
| Q1 2022 | -0.2x | Net Cash |
| Q4 2021 | -0.2x | Net Cash |
TENX has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
TENX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.0 | Oversold |
| Stochastic | 10.9 | Oversold |
TENX's weekly RSI is 29 (oversold) and its Stochastic is 11 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
TENX PE vs Healthcare Sector
TENX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
TENX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.73 | 6.9% below |
| 20 week MA | $5.79 | 72% below |
| 50 week MA | $9.98 | 84% below |
| 100 week MA | $8.18 | 80% below |
| 200 week MA | $14.9 | 89% below |
TENX is in a downtrend: it's below all five of its weekly moving averages, and 89% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over TENX on returns for 2026, with the stronger performance.
TENX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2,032.0 | $1,776.0 | -13% |
| 2021 | $1,776.0 | $1,792.0 | +0.9% |
| 2022 | $1,792.0 | $184.0 | -90% |
| 2023 | $184.0 | $22.0 | -88% |
| 2024 | $22.0 | $6.30 | -71% |
| 2025 | $6.30 | $12.7 | +101% |
| 2026 YTD | $12.7 | $1.61 | -87% |
TENX's yearly returns have swung widely, from +101% in 2025 to −90% in 2022. It's down 87% so far in 2026.